Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Non-small-cell lung cancer (NSCLC)

Details

Review Type: Rapid

Provisional Funding Algorithm
Draft Report Posted: Feb 6, 2025
Feedback Deadline: Feb 13, 2025
Final Report Posted: Apr 4, 2025

 

Last Updated : April 4, 2025

nemolizumab

Details

Key Milestones2
Call for patient/clinician input openJanuary 15, 2025
Call for patient/clinician input closedMarch 10, 2025
Submission receivedFebruary 27, 2025
Submission acceptedMarch 13, 2025
Review initiatedMarch 17, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 09, 2025
Deadline for sponsors commentsJune 18, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 11, 2025
Expert committee meeting (initial)July 23, 2025
Draft recommendation issued to sponsor-
Clarification:

- CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements.

Draft recommendation posted for stakeholder feedback-
End of feedback period-
Last Updated : August 7, 2025

tofersen

Details

Key Milestones2
Call for patient/clinician input openJanuary 15, 2025
Call for patient/clinician input closedMarch 10, 2025
Submission receivedFebruary 27, 2025
Submission acceptedMarch 13, 2025
Review initiatedMarch 17, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 09, 2025
Deadline for sponsors commentsJune 18, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 11, 2025
Expert committee meeting (initial)July 23, 2025
Draft recommendation issued to sponsorAugust 06, 2025
Draft recommendation posted for stakeholder feedbackAugust 14, 2025
End of feedback periodAugust 28, 2025
Last Updated : August 6, 2025